ArticleHeart (British Cardiac Society)2003
Evolution of statin prescribing 1994-2001: a case of agism but not of sexism?
Article in Heart (British Cardiac Society), 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it, 141 citations in OpenAlex.
- Cardiovascular medication utilization and adherence among adults living in rural and urban areas: a systematic review and meta-analysis.BMC public health · 2014Pooled it
- Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial.Annals of internal medicine · 2010 · on this mapTrial
- An economic evaluation of fluvastatin used for the prevention of cardiac events following successful first percutaneous coronary intervention in the UK.PharmacoEconomics · 2004Trial
- Use of electronic health record data from diverse primary care practices to identify and characterize patients' prescribed common medications.Health informatics journal · 2020Article
- Statins for primary prevention of cardiovascular disease: modelling guidelines and patient preferences based on an Irish cohort.The British journal of general practice : the journal of the Royal College of General Practitioners · 2019Article
- Statins for the primary prevention of cardiovascular disease: an overview of systematic reviews.BMJ open · 2019Review
- Time trends in statin use and incidence of recurrent cardiovascular events in secondary prevention between 1999 and 2013: a registry-based study.BMC cardiovascular disorders · 2018Article
- Article
- 10-year trends in statin utilization in Taiwan: a retrospective study using Taiwan's National Health Insurance Research Database.BMJ open · 2017Article
- Association Between Preadmission Functional Status and Use and Effectiveness of Secondary Prevention Medications in Elderly Survivors of Acute Myocardial Infarction.Journal of the American Geriatrics Society · 2016Article
- Time trends in the prescription of statins for the primary prevention of cardiovascular disease in the United Kingdom: a cohort study using The Health Improvement Network primary care data.Clinical epidemiology · 2016Article
- Extracting Electronic Health Record Data in a Practice-Based Research Network: Processes to Support Translational Research across Diverse Practice Organizations.EGEMS (Washington, DC) · 2016Article
- Article
- Article
- Article
- Factors associated with statin treatment for the primary prevention of cardiovascular disease in people within 2 years following diagnosis of diabetes in Scotland, 2006-2008.Diabetic medicine : a journal of the British Diabetic Association · 2014Article
- Social stratification in the dissemination of statins after stroke in Sweden.European journal of clinical pharmacology · 2013Article
- Statin use among older Finns stratified according to cardiovascular risk.European journal of clinical pharmacology · 2013Article
- Influence of patients' coronary artery calcium on subsequent medication use patterns.American journal of health behavior · 2012Article
- Statins and their interactions with other lipid-modifying medications: safety issues in the elderly.Therapeutic advances in drug safety · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveTo study trends in the use of lipid lowering drugs in the UK, and to assess which patient factors influence prescribing.
methodsRoutinely collected computerised medical data were analysed from 142 general practices across England and Wales that provide data for the Doctors' Independent Network database. Subjects included were people aged 35 years or more with treated ischaemic heart disease, averaging annually over 30,000. The temporal trend from 1994 to 2001 in prescription of lipid lowering drugs and daily statin dose and the odds ratios (ORs) for receiving a statin prescription in 1998 were examined.
resultsLipid lowering drug prescribing increased greatly over time, entirely because of statins, so that in 2001 56.3% of men and 41.1% of women with ischaemic heart disease received lipid lowering drugs. However, 33% of these patients were on a < 20 mg simvastatin daily equivalent. In 1998 the OR for receiving a statin fell from 1 at age 55-64 to 0.64 at 65-74 and 0.16 at 75-84 years. The age effect was similar in those without major comorbidity. Revascularised patients were much more likely to receive a statin than those with angina (OR 3.92, 95% confidence interval (CI) 3.57 to 4.31). Men were more likely to receive a statin than women (OR 1.62, 95% CI 1.54 to 1.71) but this difference disappeared after adjustment for age and severity of disease (OR 1.06). Geographical region had little effect but there was a very weak socioeconomic gradient.
conclusionsAlthough prescribing has increased, many patients who may benefit from lipid lowering drugs either do not receive it or are undertreated, possibly because of lack of awareness of the relative potency of the different statins. Patients with angina and the elderly are less likely to receive treatment that may prevent a coronary event.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.